


58. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on sub- sequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood 2009;114:72–77.


203. Ribeira JM, Orsiol A, Rethorouc C, et al. Comparison of intensive chemo-
therapy, autologous or allologous stem cell transplantation as post-remission
therapy for adult patients with high-risk acute lymphoblastic leukemia.

204. Marks DJ, Forman SJ, Blume KG, et al. A comparison of cyclophospha-
damide, total body irradiation with etoposide and total body irradiation as
conditioning regimen for patients undergoing sibling allografting for acute
lymphoblastic leukemia in first or second complete remission. Biol Blood

205. Blume KG, Kopecky KJ, Hensley-Downey J, et al. A prospective ran-
domized comparison of total body irradiation-etoposide versus busulphan-
cyclophosphamide as preparatory regimens for bone marrow transplantation
in patients with chronic myeloid leukemia who were in first remission. A Southwest Oncol-

206. Marks DJ, Ward, P, Perez WS, et al. The outcome of full-intensity and
reduced-intensity conditioning matching sibling or unrelated donor transplan-
tation in adults with Philadelphia chromosome-negative acute lymphoblastic

207. Mohly M, Labopin M, Taherzadeh K, et al. Reduced intensity conditioning
al-
logeneic stem cell transplantation for adult patients with acute lymphoblas-
tic leukemia: a retrospective study from the European Group for Blood and

followed by peripheral blood stem cell transplantation for adult patients

209. Hamaki T, Kanai M, Kanda Y, et al. Reduced-intensity stem-cell transplanta-
tion for adult acute lymphoblastic leukemia: a retrospective study of 37 pa-

therapy for adult patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic

211. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict
the outcome of patients with Philadelphia chromosome-positive ALL treated


Philadelphia chromosome-positive acute lymphoblastic leukemia: a report from the large randomized prospective trial (UKALL XII/ECOG

214. Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-
CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymph-
oma or acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to in-
duction treatment in patients enrolled in the GIMEMA LAL 0496 protocol.

215. Marks DJ, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic
leukemia in adults: clinical features, immunophenotype, cytogenetics, and
outcome from the large randomized prospective trial (UKALL XII/ECOG

216. DeAngelis DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remis-
sions in adults with relapsed or refractory T-lineage acute lymphoblastic

217. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-
cytosine arabinoside for the treatment of refractory acute lymphocytic leuke-

218. Laport GG, Alvarnas JC, Palmer JM, et al. Long-term remission of
Philadelphia chromosome-positive acute lymphoblastic leukemia after al-
logeneic hematopoietic cell transplantation from matched sibling donor:
A 20-year experience with the fractionated total body irradiation–etoposide

tients with Philadelphia chromosome-positive acute lymphoblastic leukemia
treated with allogeneic bone marrow transplant in first complete remission.

220. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267
unselected adult patients with Philadelphia chromosome-positive acute
lymphoblastic leukaemia confirm superior outcome of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL

221. Cornelsen JJ, Carston M, Kollman C, et al. Unrelated marrow transplanta-
tion for adult patients with poor-risk acute lymphoblastic leukemia: strong

222. Ottmann OG, Pfeifer H, et al. Imatinib compared with chemo-
therapy as front-line treatment of elderly patients with Philadelphia chromo-
some-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer 2007;109:
2068–2076.

2351–2354.

CML and Philadelphia chromosome–positive ALL. N Engl J Med 2006;354:
2354–2351.

gic and cytogenetic responses in patients with imatinib-resistant or intolerant variants of chronic myeloid leukemia who were in first remission, the Southwest Oncol-

2309–2315.

on the outcome of: acute myeloid leukemia in adults with newly diagnosed
Philadelphia chromosome-positive acute lymphoblastic leukemia.

the GIMEMA GRIAPH 2005 study in newly diagnosed patients with de

remissions and prolonged survival in elderly Philadelphia chromosome–
positive patients with acute lymphoblastic leukemia without additional che-


